PolyPid (NASDAQ:PYPD) Upgraded by HC Wainwright to “Buy” Rating

PolyPid (NASDAQ:PYPD) was upgraded by research analysts at HC Wainwright to a “buy” rating in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The firm presently has a $11.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 272.88% from the company’s previous close. HC Wainwright also issued estimates for PolyPid’s FY2027 earnings at ($0.59) EPS, FY2028 earnings at $0.00 EPS and FY2029 earnings at $1.34 EPS.

PolyPid Price Performance

Shares of PYPD opened at $2.95 on Monday. PolyPid has a 12-month low of $2.30 and a 12-month high of $4.50. The business’s fifty day moving average is $2.70 and its 200 day moving average is $2.92. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.08. The stock has a market cap of $30.06 million, a P/E ratio of -0.59 and a beta of 1.25.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, May 14th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.10. Sell-side analysts anticipate that PolyPid will post -1.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PolyPid

Large investors have recently modified their holdings of the company. J. Goldman & Co LP bought a new position in PolyPid during the 4th quarter valued at $391,000. AIGH Capital Management LLC lifted its stake in PolyPid by 21.8% during the 4th quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after acquiring an additional 148,199 shares in the last quarter. Finally, Rosalind Advisors Inc. lifted its stake in PolyPid by 49.9% during the 4th quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock valued at $3,095,000 after acquiring an additional 338,853 shares in the last quarter. 26.47% of the stock is currently owned by institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.